Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position.
Durrant starts by highlighting that Scancell has "plenty of money" before going into more detail about what's been happening with its two lead compounds, SCIB1 and Modi-1.
She also touches on progress in the relationship with Genmab (CSE:GEN) since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal."
She adds that the company is "well financed" with a runway extending into the second half of 2024, but makes it clear that the continued emergence of promising clinical data could make a fundraise necessary - saying that "clearly a company of our size always needs to think about that as we go forward."